News for Evotec SE (EVTCY)

Deutsche Bank has revised its rating for Evotec (EVO), upgrading the stock from a "Sell" to a "Hold" recommendation. Additionally, the bank increased its price

Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needsPerformance-based and program-based payments of in

Evotec SE (NASDAQ:EVO) received a milestone payment of $75 million from Bristol Myers Squibb. The collaboration focuses on developing molecular glue deg

Group Revenue: EUR797 million, a 2% increase versus 2023.Shared R&D Revenue: Declined from EUR673 million in 2023 to EUR611 million in 2024.Just - Evotec Biolo

Apr 17, 2025 / 12:00PM GMTOperator Ladies and gentlemen, Welcome to the Evotec SE full-year result 2024 analyst call. I am Yousef, the call operator. I would li

U.S. stocks were lower, with the Dow Jones index falling around 550 points on Thursday. Shares of uniQure N.V. QURE rose sharply during Thursday's session afte...

The major U.S. index futures are currently pointing to a higher open on Thursday, with stocks likely to regain ground following the sell-off seen over the course of the previous session.

Key Takeaways: Evolution Gaming (EVO) experiences a 7% dip amidst market fluctuations, though it maintains a solid five-year growth trajectory. Analysts

Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growthStrategy builds on technology and science leadershi

European stocks drifted lower on Thursday as investors fretted about the impact of U.S. President Donald Trump's erratic trade policies on inflation, interest rates and global growth.

Evotec SE shows robust Q4 revenue growth with future projections indicating continued strength. Analyst price targets suggest significant potential upsi

Evotec SE (EVO) reports a 2% revenue increase to €797.0 million for FY 2024, with Q4 revenues up 10% to €221.2 million. The Just - Evotec Biologics

HAMBURG, DE / ACCESS Newswire / April 10, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its finan

Evotec SE (EVO) to announce its 2024 financial results on April 17, 2025. The company will host a conference call at 2:00 PM CEST to discuss the results

Ongoing strategic partnership advances joint pipeline in neurodegeneration researchEvotec receives a $20 million payment to further progress research HAMBURG, D

Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025Paul Hitchin appointed to succeed as Chief Financial Officer effective 1 March 2

PR NewswireSYDNEY, Jan. 14, 2025 SYDNEY, Jan. 14, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-fo

Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

PR NewswireSYDNEY, Jan. 10, 2025 SYDNEY, Jan. 10, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-fo